Drug Profile
Immuno-modulatory therapeutics - Bristol-Myers Squibb
Alternative Names: STING agonists - Bristol-Myers SquibbLatest Information Update: 08 Feb 2023
Price :
$50
*
At a glance
- Originator IFM therapeutics
- Developer Bristol-Myers Squibb
- Class Antineoplastics; Small molecules
- Mechanism of Action Immunomodulators; MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 08 Feb 2023 Discontinued - Phase-I for Cancer in USA (unspecified route)
- 23 Feb 2022 Phase I development is ongoing USA (Bristol Myers Squibb pipeline, February 2022)
- 23 Feb 2022 Phase-I clinical trials in Cancer in USA (Bristol Myers Squibb pipeline, February 2022)